Why is Cooper Companies stock plunging today?
Cooper Companies (COO) stock fell 15.3% in after-hours trading to $53.80 after reporting fiscal Q3 2026 results and deciding not to sell its CooperSurgical unit. Non-GAAP EPS beat estimates at $1.15, while revenue grew 1% to $1.066 billion. The company issued cautious Q4 guidance and expanded its share repurchase program to $3 billion. The broader market had minimal impact on the stock's decline.
How this was made
The 30-second read
Why it matters
The board’s decision to retain CooperSurgical, despite offers, removed the expected catalyst for value realization and coincided with guidance that implied only 2-3% organic growth, amplifying downside sentiment.
Market read
Traders should treat this as a fresh fundamental reset: strategic review outcome changed the expected capital allocation path, and guidance plus inventory warnings added execution risk.
What to watch
The article highlights two bid headwinds (non-hormonal IUD competition and a fertility litigation settlement impact), so the market may be over-weighting near-term uncertainty versus longer-term product and cost actions.
Background
Cooper Companies launched a strategic review in Dec 2025 under activist pressure, with market expectations centered on a potential divestiture of CooperSurgical.
Ticker impact
Cooper Companies shares plunged after-hours after it reported fiscal Q3 results and ended its strategic review without selling CooperSurgical.
Bearish near-term bias, with elevated volatility until investors reassess the growth outlook and inventory normalization path.
The article attributes the 15.3% after-hours drop to the strategic review ending in a retention decision, alongside underwhelming full-year guidance and a CooperVision inventory reduction warning.
Market effects
Medical device investors may reprice women’s health and fertility peers if guidance conservatism and competitive pressure in IUDs spreads.
Limited, as the article says broad US indices were essentially flat and the move was company-specific.
Low, no cross-market policy or global regulatory catalyst is cited.
Counterpoint
The expanded $3B share repurchase authorization could partially offset the no-sale disappointment if investors believe retained assets can be improved operationally.
Key entities
- companyCooper Companies
Medical device maker whose fiscal Q3 results and strategic review outcome drove the after-hours selloff.
- business_unitCooperSurgical
Women’s health and fertility unit retained after the strategic review concluded no sale.
- business_unitCooperVision
Ophthalmology unit whose US channel inventory reductions were cited as a continuing headwind.
- executiveAl White
CEO who cautioned that inventory reductions at CooperVision would impact Q4 results.
